

CURRICULUM VITAE



Name: Kuan-Hsuan Chen (陳寬軒)

Office Address: Department of Pharmacy
Taipei Veterans General Hospital
Taipei, Taiwan 11217

E-mail: khchen3@vghtpe.gov.tw

Education:

1. 2016, National Yang Ming University, Institute of Clinical Medicine (Ph.D.)
2. 2006, China Medical University, School of Pharmacy (B.S.)

Training:

Osaka Prefecture University/Kyoto University Hospital, cancer research
Anticoagulant training program level I & II
Certified Diabetes Educator (CDE)

Research Interests:

Boron neutron capture therapy (GBM, head and neck cancer), stem cells, induced pluripotent stem cells, cancer stem-like cells, oxidative stress, drug-screening platform, clinical pharmacy

Hospital Appointments:

1. 2008-present, clinical pharmacist in Department of Pharmacy, Taipei Veterans General Hospital
 - 2014-present, anticoagulation clinic
 - 2012-present, neurology care, NCUA, NCUB, SCU
 - 2008-2012, cardiology care, CCU
2. 2011~present, PGY preceptor in Department of Pharmacy, Taipei Veterans General Hospital
3. 2008~present, UGY preceptor in Department of Pharmacy, Taipei Veterans General Hospital
4. 2012~2013, leader of medical quality & patient safety in Department of Pharmacy, Taipei Veterans General Hospital
5. 2011~2014, vice leader of International Affairs Committee in Taipei Pharmacists Association
6. 2007~2008, pharmacist in Department of Pharmacy, Taipei Veterans General Hospital

Awards:

1. 2020, the best teacher in Department of Pharmacy, Taipei Veterans General Hospital
2. 2019, the best clinical pharmacist in Department of Pharmacy, Taipei Veterans General Hospital
3. 2019, the best PGY preceptor in Department of Pharmacy, Taipei Veterans General Hospital
4. 2016, the best PGY preceptor in Department of Pharmacy, Taipei Veterans General Hospital
5. 2012, the best UGY preceptor in Department of Pharmacy, Taipei Veterans General Hospital
6. 2010, the best teacher in Department of Pharmacy, Taipei Veterans General Hospital

Publication:

1. Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, Chang YL. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. J Chin Med Assoc.2020 Jun 15.
2. Wang SF, Chen KH, Wang SY, Yarmishyn AA, Lai WY, Lin YY, Wang ML, Chou SJ, Yang YP, Chang YL. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2. J Chin Med Assoc.2020 May 18.
3. Wang CY, Yang YP, Liu CY, Lu KH, Liu YY, Wu WW, Chen KH, Chang YL, Lee SD, Lin HC. Nanoparticle-delivery system enhanced the improvement and recovery in toxicity-induced acute hepatic failure. J Chin Med Assoc. 2019 May;82(5):363-367.
4. Wang CY, Huang CS, Yang YP, Liu CY, Liu YY, Wu WW, Lu KH, Chen KH, Chang YL, Lee SD, Lin HC. The subpopulation of CD44-positive cells promoted tumorigenicity and metastatic ability in lung adenocarcinoma. J Chin Med Assoc. 2019 Mar;82(3):196-201
5. Chen KH, Hsiang EL, Hsu MY, Chou YC, Lin TC, Chang YL, Tsai CY, Li TH, Woung LC, Chen SJ, Peng CH, Hwang DK. Elevation of serum oxidative stress in patients with retina vein occlusions. Acta Ophthalmol. 2018 Sep 26
6. Chien Y, Chou SJ, Chang YL, Leu HB, Yang YP, Tsai PH, Lai YH, Chen KH, Chang WC, Sung SH, Yu WC. Inhibition of Arachidonate 12/15-Lipoxygenase Improves α -Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from

- Fabry Patients. *Int J Mol Sci*. 2018 May 16;19(5).
7. Chien Y, Huang CS, Lin HC, Lu KH, Tsai PH, Lai YH, Chen KH, Lee SD, Huang YH, Wang CY. Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4/Sox2/Klf4/Parp1. *Oncotarget*. 2018 Jan 2;9(26):18594-18606.
 8. Chen KH, Chou YC, Hsiao CY, Chien Y, Wang KL, Lai YH, Chang YL, Niu DM, Yu WC. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. *Biochem Biophys Res Commun*. 2017;486:293-99.
 9. Tseng WL, Chou SJ, Chiang HC, Wang ML, Chien CS, Chen KH, Leu HB, Wang CY, Chang YL, Liu YY, Jong YJ, Lin SZ, Chiou SH, Lin SJ, Yu WC. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells. *Cell Transplant*. 2017;26:513-27.
 10. Chien Y, Chien CS, Chiang HC, Huang WL, Chou SJ, Chang WC, Chang YL, Leu HB, Chen KH, Wang KL, Lai YH, Liu YY, Lu KH, Li HY, Sung YJ, Jong YJ, Chen YJ, Yu WC. Interleukin-18 Deteriorates Fabry Cardiomyopathy and Contributes to the Development of Fabry-associated Left Ventricular Hypertrophy. *Oncotarget*. 2016;7:87161-179.
 11. Chen KH, Chien Y, Wang KL, Leu HB, Hsiao CY, Lai YH, Wang CY, Chang YL, Lin SJ, Niu DM, Chiou SH, Yu WC. Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy. *Can J Cardiol*. 2016;32:1221.e1-e9.
 12. Chien Y, Chang YL, Li HY, Larsson M, Wu WW, Chien CS, Wang CY, Chu PY, Chen KH, Lo WL, Chiou SH, Lan YT, Huo TI, Lee SD, Huang PI. Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. *Acta Biomater*. 2015;13:228-44.
 13. Chiou GY, Chien CS, Wang ML, Chen MT, Yang YP, Yu YL, Chien Y, Chang YC, Shen CC, Chio CC, Lu KH, Ma HI, Chen KH, Liu DM, Miller SA, Chen YW, Huang PI, Shih YH, Hung MC, Chiou SH. Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. *Mol Cell*. 2013;52:693-706.

14. Wung JC、Chen KH、Chang YL. Heart failure. Journal of Hospital Pharmacy 2013 Mar.
15. Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J Pharmacol Exp Ther. 2012;341:410-23.
16. Huang PI, Chou YC, Chang YL, Chien Y, Chen KH, Song WS, Peng CH, Chang CH, Lee SD, Lu KH, Chen YJ, Kuo CH, Hsu CC, Lee HC, Yung MC. Enhanced differentiation of three-gene-reprogrammed induced pluripotent stem cells into adipocytes via adenoviral-mediated PGC-1 α overexpression. Int J Mol Sci. 2011;12:7554-68.
17. Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng LM, Song WS, Wang JJ, Lin JK, Huang PI, Lan YT. Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun. 2011;415:245-51.
18. Chen YW*, Chen KH*, Huang PI*, Chen YC, Chiou GY, Lo WL, Tseng LM, Hsu HS, Chang KW, Chiou SH. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells. Mol Cancer Ther. 2010;9:2879-92.
19. Chen KH, Hsu CC, Song WS, Huang CS, Tsai CC, Kuo CD, Hsu HS, Tsai TH, Tsai CY, Woung LC, Chiou SH, Lu KH, Chen YW. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Childs Nerv Syst. 2010;26:1605-12.
20. Yang DM, Teng HC, Chen KH, Tsai ML, Lee TK, Chou YC, Chi CW, Chiou SH, Lee CH. Clodronate-induced cell apoptosis in human thyroid carcinoma is mediated via the P2 receptor signaling pathway. J Pharmacol Exp Ther. 2009;330:613-23.
21. Chen KH、Chang YL、Chou YC. New drug for hypertension–Aliskiren. Journal of Hospital Pharmacy. 2009 Sep.

Presentations/Posters:

1. Evaluation BNCT in cancer stem-like cells. International conference of translational medicine and advanced therapeutics in Taipei 2019 Dec.
2. Evaluation BNCT in head and neck cancer. Kyoto/Osaka-Taiwan international

- BNCT conference. Osaka Medical University 2019 Mar.
3. Introduction of Pharmaceutical Research in Department of Pharmacy. Vietnam- Taiwan Bilateral Conference. Hanoi Medical University 2019 Mar.
 4. Development of S-alkyl-closo-dodecaborate-coataining amino acids as boron carrier for BNCT. International Congress on Neutron Capture Therapy. Taiwan 2018
 5. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of Fabry-associated left ventricular hypertrophy. The Pharmaceutical Society of Taiwan. Taipei Medical University 2016
 6. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. The Pharmaceutical Society of Taiwan. National Defense University 2013
 7. Evaluation of tamoxifen in pharmacogenetics. The Pharmaceutical Society of Taiwan. China Medical University 2012
 8. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)/ALDH1(+) cells. American Association for Cancer Research. Orlando Florida U.S.A. 2011
 9. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. The Pharmaceutical Society of Taiwan. Taipei Medical University 2009

Research projects:

1. 2020 Taipei Veterans General Hospital. Evaluation BNCT in cancer stem-like cell.
2. 2018 Taipei Veterans General Hospital. Evaluation anti-depressant drug on iPSC platform.
3. 2017 Taipei Veterans General Hospital. miR-124 and miR-145 regulation in nervous system development and protection mechanisms.
4. 2016 Taipei Veterans General Hospital. The Role of MicroRNA-145 in Glioblastoma Multiforme.
5. 2011 Taipei Veterans General Hospital. Study the mechanism of celecoxib in glioblastoma-derived tumor stem-like cells.

Licensure:

1. Licentiate in Pharmacy
2. Certified Diabetes Educator (CDE)
3. Anticoagulant training program level I & II

Membership in professional organizations:

1. American Association for Cancer Research (AACR)

2. Taipei Pharmacists Association (TPA)
3. The Pharmaceutical Society of Taiwan
4. Taiwan Society of Health-System Pharmacists (TSHP)
5. Taiwanese Association of Diabetes Educators (TADE)
6. Taiwan Society of Neutron Capture Therapy (TSNCT)

References:

Available upon request